Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Gains from Investment Securities (2017 - 2025)

Crinetics Pharmaceuticals has reported Gains from Investment Securities over the past 9 years, most recently at $42000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $42000.0 for Q4 2025, down 17.65% from a year ago — trailing twelve months through Dec 2025 was -$615000.0 (up 90.16% YoY), and the annual figure for FY2024 was $13.7 million, up 8.23%.
  • Gains from Investment Securities for Q4 2025 was $42000.0 at Crinetics Pharmaceuticals, down from $15.0 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for CRNX hit a ceiling of $15.0 million in Q2 2025 and a floor of -$5.6 million in Q4 2022.
  • Median Gains from Investment Securities over the past 5 years was $2.1 million (2025), compared with a mean of $5.3 million.
  • Peak annual rise in Gains from Investment Securities hit 138529.1% in 2022, while the deepest fall reached 62322.22% in 2022.
  • Crinetics Pharmaceuticals' Gains from Investment Securities stood at $9000.0 in 2021, then plummeted by 62322.22% to -$5.6 million in 2022, then surged by 87.36% to -$708000.0 in 2023, then skyrocketed by 107.2% to $51000.0 in 2024, then fell by 17.65% to $42000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $42000.0 (Q4 2025), $15.0 million (Q2 2025), and $2.1 million (Q1 2025) per Business Quant data.